LCK: IHC Expression in Cancer and Radioligand Target Profile
LCK, LCK proto-oncogene, Src family tyrosine kinase, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, LCK staining is highest in lymphoma (100% of samples positive), pancreatic cancer (25% of samples positive) and colorectal cancer (17% of samples positive). Clinical status: FDA-approved drug (any modality).
Is LCK the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze LCK freeIs LCK a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in lymphoma, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
LCK IHC staining by cancer type
Protein expression of LCK across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lymphoma | 0.89 | High | 100% |
| Pancreatic Cancer | 0.14 | Low | 25% |
| Colorectal Cancer | 0.08 | Low | 17% |
| Prostate Cancer | 0.04 | Low | 11% |
| Liver Cancer | 0.03 | Low | 10% |
| Testicular Cancer | 0.03 | Low | 8% |
Not detected by IHC in: skin cancer, head and neck cancer, ovarian cancer, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, gastric cancer, endometrial cancer, glioma.
Is LCK internalized?
Nuclens has not yet extracted internalization evidence for LCK. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
LCK clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for LCK yet. Search ClinicalTrials.gov for LCK trials.
LCK normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See LCK in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
LCK gene essentiality (DepMap)
CRISPR knockout effect across 1247 cancer cell lines: 0.00 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lymphoma radioligand targets
c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD19 · CD45 (PTPRC) · SSTR2 · CD22 · STEAP2
See all radioligand therapy targets in lymphoma.
See how LCK ranks against 15,000 targets for your indication.
Analyze LCK freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.